A string of positive news continues for Boston Scientific (NYSE: BSX), which this week announced FDA approval for its next-generation Watchman FLX.
Last week, the company reported positive data for its Farapulse system, which led to a favorable reaction from analysts and the market. Just the week before, Boston Scientific received expanded FDA 510(k) clearance for its Visual Ice cryoablation system. Visual Ice’s approval came just weeks after the FDA approved the company’s POLARx cryoablation system for treating paroxysmal AFib.
Watchman FLX Pro, the company’s latest left atrial appendage closure (LAAC) device, further advances Watchman’s performance and safety. It’s indicated for reducing stroke risk in patients with non-valvular AFib (NVAF) who need an alternative to oral anticoagulation therapy.
Boston Scientific designed its next-generation device with a polymer coating, visualization markers and a broader size matrix. The company says this design helps to treat a wider range of patients.
